Results
|
|
1.
|
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. MedStar authors:
Year: 2019
Citation: - Diabetes Technology & Therapeutics. 21(5):273-285, 2019 May.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bailey TS, Bergenstal RM, Brazg RL, Calibra Study Group, Dreon DM, Frias JP, Johnson ML, Klonoff DC, Kruger DF, Levy BL, Naik RG, Peyrot M, Ramtoola S, Rosenstock J, Serusclat P, Shearer DM, Weinstock RS, Zraick V
|
|
|
5.
|
|
|
|
6.
|
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(6):1706-11, 2014 Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Reaven PD, Schwenke DC, Stentz FB, Tripathy D
|
|
|
7.
|
|
|
|
8.
|
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. MedStar authors:
Year: 2018
Citation: - The Lancet Diabetes & Endocrinology. 6(4):275-286, 2018 04.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andreassen C, Aroda VR, Lingvay I, Ludemann J, Navarria A, Pratley RE, SUSTAIN 7 investigators, Viljoen A
|
|
|
9.
|
|
|
|
10.
|
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction. [Review] MedStar authors:
- Lam, Phillip H
- Patel, Jay
- Rassekh, Negin
- Sheikh, Farooq H
Year: 2023
Citation: - Drugs. 83(9):747-759, 2023 Jun.
Institution:
- MedStar Heart & Vascular Institute
- MedStar Washington Hospital Center
Department: - Cardiovascular Disease Fellowship
Medline publication type:
All authors: - Ahmed A, Deedwania P, Fonarow GC, Lam PH, Patel J, Rassekh N, Sheikh FH
|
|
|
11.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(9):1579-86, 2016 Sep
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
|
|
|
12.
|
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C
|
|
|
13.
|
|
|
|
14.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
|
|
15.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
|
|
|
16.
|
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).[Erratum appears in Diabetes Obes Metab. 2016 Sep;18(9):952; PMID: 27546838] MedStar authors:
Year: 2016
Citation: - Diabetes, Obesity & Metabolism. 18(7):663-70, 2016 Jul
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andersen TH, Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Philis-Tsimikas A, Raskin P, Zacho J
|
|
|
17.
|
|
|
|
18.
|
Synergy to reduce emergency department visits for uncontrolled hyperglycemia. MedStar authors:
- Dubin, Jeffrey S
- Fokar, Ali
- Magee, Michelle F
- Nassar, Carine M
- Sharretts, John M
- Smith, Mark S
Citation: - Diabetes Educator. 39(3):354-64, 2013 May-Jun.
Institution:
- MedStar Diabetes Institute
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Department:
- Emergency Medicine
- Medicine/Endocrinology
- MedStar Diabetes Institute
Medline publication type:
- Evaluation Studies
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Copeland J, Dubin JS, Fokar A, Magee MF, Nassar CM, Sharretts JM, Smith MS
|
|
|
19.
|
Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). MedStar authors:
- Fatemi, Omid
- Yuriditsky, Eugene
Citation: - American Journal of Cardiology. 114(8):1217-22, 2014 Oct 15.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Basile J, Bigger T, Cushman W, Fatemi O, Goff D, Morgan T, Papademetriou V, Soliman EZ, Thomas A, Tsachris D, Tsioufis C, Yuriditsky E
|
|
|
20.
|
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. [] MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(8):2317-25, 2014 Aug.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Ahren B, Chow FC, Fonseca VA, Gross JL, Harmony 6 Study Group, Johnson SL, Leiter LA, Miller D, Ratner RE, Rosenstock J, Stewart MW, Yang F
|
|
|
21.
|
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. MedStar authors:
Year: 2018
Citation: - Diabetes Care. 41(2):258-266, 2018 02.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Ahmann AJ, Annett MP, Aroda VR, Capehorn M, Charpentier G, Dotta F, Henkel E, Holst AG, Lingvay I
|
|
|
22.
|
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(11):2108-2116, 2019 11.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Blonde L, Del Prato S, Frias J, Henry R, Ji C, Niemoeller E, Rosenstock J, Shehadeh N, Souhami E
|
|
|
23.
|
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. MedStar authors:
Year: 2020
Citation: - Diabetes Care. 43(5):940-947, 2020 05.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Butera NM, Camp AW, Cherrington A, Craig J, Fortmann SP, GRADE Research Group, Hollander PA, Krakoff J, Perez M, Phillips LS, Rasouli N, Sivitz WI, Tan MH, Tiktin M, Wexler DJ, Younes N
|
